

Stuart Jon Spechler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/304004/publications.pdf>

Version: 2024-02-01

155
papers

18,322
citations

26630
56
h-index

12272
133
g-index

209
all docs

209
docs citations

209
times ranked

8332
citing authors

#	ARTICLE	IF	CITATIONS
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. Journal of Allergy and Clinical Immunology, 2011, 128, 3-20.e6.	2.9	1,839
2	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine, 2009, 360, 2277-2288.	27.0	1,348
3	American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. Gastroenterology, 2011, 140, e18-e52.	1.3	968
4	American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. Gastroenterology, 2011, 140, 1084-1091.	1.3	909
5	Long-term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease. JAMA - Journal of the American Medical Association, 2001, 285, 2331.	7.4	817
6	Barrett's Esophagus. New England Journal of Medicine, 1986, 315, 362-371.	27.0	740
7	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology, 2018, 155, 1022-1033.e10.	1.3	712
8	A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Ja. Gastroenterology, 2004, 127, 310-330.	1.3	579
9	Barrett's Esophagus. New England Journal of Medicine, 2002, 346, 836-842.	27.0	571
10	Comparison of Medical and Surgical Therapy for Complicated Gastroesophageal Reflux Disease in Veterans. New England Journal of Medicine, 1992, 326, 786-792.	27.0	561
11	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology, 2011, 141, 460-468.	1.3	432
12	Barrett's Esophagus. New England Journal of Medicine, 2014, 371, 836-845.	27.0	432
13	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. Gastroenterology, 2012, 143, 336-346.	1.3	365
14	Thoughts on the Complex Relationship Between Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. American Journal of Gastroenterology, 2007, 102, 1301-1306.	0.4	328
15	Gastroesophageal Reflux Might Cause Esophagitis Through a Cytokine-Mediated Mechanism Rather Than Caustic Acid Injury. Gastroenterology, 2009, 137, 1776-1784.	1.3	327
16	ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2022, 117, 27-56.	0.4	313
17	Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut, 2013, 62, 824-832.	12.1	286
18	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut, 2016, 65, 524-531.	12.1	279

#	ARTICLE	IF	CITATIONS
19	Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications. Digestive Diseases and Sciences, 2009, 54, 2312-2317.	2.3	275
20	Barrett Esophagus and Risk of Esophageal Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 627.	7.4	240
21	Omeprazole Blocks STAT6 Binding to the Eotaxin-3 Promoter in Eosinophilic Esophagitis Cells. PLoS ONE, 2012, 7, e50037.	2.5	203
22	Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology, 2002, 122, 299-307.	1.3	196
23	Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA - Journal of the American Medical Association, 2016, 315, 2104.	7.4	190
24	AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology, 1999, 117, 233-254.	1.3	182
25	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. Gastroenterology, 2010, 138, 854-869.	1.3	181
26	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. New England Journal of Medicine, 2019, 381, 1513-1523.	27.0	178
27	Acid, Bile, and CDX: the ABCs of making Barrett's metaplasia. American Journal of Physiology - Renal Physiology, 2008, 295, G211-G218.	3.4	167
28	Buried Metaplasia After Endoscopic Ablation of Barrett's Esophagus: A Systematic Review. American Journal of Gastroenterology, 2011, 106, 1899-1908.	0.4	162
29	The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology, 1999, 117, 218-228.	1.3	161
30	Diagnostic inconsistencies in Barrett's esophagus. Gastroenterology, 1994, 107, 945-949.	1.3	158
31	Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus. American Journal of Surgical Pathology, 2009, 33, 1006-1015.	3.7	156
32	Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Ecological Management and Restoration, 2008, 21, 43-50.	0.4	146
33	Hallmarks of cancer progression in Barrett's oesophagus. Lancet, The, 2002, 360, 1587-1589.	13.7	141
34	Dysplasia in Barrett's Esophagus: Limitations of Current Management Strategies. American Journal of Gastroenterology, 2005, 100, 927-935.	0.4	111
35	Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF- κ B activation in benign Barrett's epithelial cells. American Journal of Physiology - Renal Physiology, 2011, 301, G278-G286.	3.4	110
36	Pathogenesis and Cells of Origin of Barrett's Esophagus. Gastroenterology, 2019, 157, 349-364.e1.	1.3	104

#	ARTICLE	IF	CITATIONS
37	Tissue remodeling in eosinophilic esophagitis. American Journal of Physiology - Renal Physiology, 2012, 303, G1175-G1187.	3.4	98
38	A Systematic Review of the Risk of Perforation During Esophageal Dilation for Patients with Eosinophilic Esophagitis. Digestive Diseases and Sciences, 2010, 55, 1512-1515.	2.3	95
39	Might the Use of Acid-Suppressive Medications Predispose to the Development of Eosinophilic Esophagitis?. American Journal of Gastroenterology, 2009, 104, 1897-1902.	0.4	90
40	Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. American Journal of Gastroenterology, 2015, 110, 967-977.	0.4	90
41	In Benign Barrett's Epithelial Cells, Acid Exposure Generates Reactive Oxygen Species That Cause DNA Double-Strand Breaks. Cancer Research, 2009, 69, 9083-9089.	0.9	89
42	Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Digestive Diseases and Sciences, 1993, 38, 97-108.	2.3	85
43	Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. Journal of Clinical Investigation, 2014, 124, 3767-3780.	8.2	81
44	Fundoplication and the Risk of Esophageal Cancer in Gastroesophageal Reflux Disease: A Veterans Affairs Cohort Study. American Journal of Gastroenterology, 2005, 100, 1002-1008.	0.4	80
45	Prevalence and Significance of Pancreatic Acinar Metaplasia at the Gastroesophageal Junction. American Journal of Surgical Pathology, 1996, 20, 1507-1510.	3.7	79
46	Management Options for Patients With GERD and Persistent Symptoms on Proton Pump Inhibitors: Recommendations From an Expert Panel. American Journal of Gastroenterology, 2018, 113, 980-986.	0.4	78
47	Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach. Ca-A Cancer Journal for Clinicians, 2005, 55, 334-351.	329.8	77
48	Intestinal metaplasia at the gastroesophageal junction. Gastroenterology, 2004, 126, 567-575.	1.3	68
49	Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial. American Journal of Gastroenterology, 2006, 101, 1964-1971.	0.4	66
50	Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. American Journal of Physiology - Renal Physiology, 2004, 287, G743-G748.	3.4	64
51	Efficacy of Prophylactic Hemoclips in Prevention of Delayed Post-Polypectomy Bleeding in Patients With Large Colonic Polyps. Gastroenterology, 2019, 157, 967-976.e1.	1.3	63
52	Barrett's esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Medical Clinics of North America, 2002, 86, 1423-1445.	2.5	62
53	The Management of Patients Who Have "Failed" Antireflux Surgery. American Journal of Gastroenterology, 2004, 99, 552-561.	0.4	62
54	Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. American Journal of Physiology - Renal Physiology, 2011, 300, G454-G460.	3.4	62

#	ARTICLE	IF	CITATIONS
55	In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor- κ B and activator protein-1. <i>Gut</i> , 2014, 63, 1042-1052.	12.1	62
56	Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders?. <i>American Journal of Gastroenterology</i> , 2018, 113, 1594-1599.	0.4	61
57	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	4.4	57
58	JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. <i>PLoS ONE</i> , 2016, 11, e0157376.	2.5	54
59	In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G129-G139.	3.4	53
60	Use of proton pump inhibitors and subsequent risk of celiac disease. <i>Digestive and Liver Disease</i> , 2014, 46, 36-40.	0.9	53
61	High-Frequency Probe Ultrasonography Has Limited Accuracy for Detecting Invasive Adenocarcinoma in Patients with Barrett's Esophagus and High-Grade Dysplasia or Intramucosal Carcinoma: A Case Series. <i>American Journal of Gastroenterology</i> , 2006, 101, 1773-1779.	0.4	51
62	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 243-256.	2.2	48
63	Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. <i>Gastroenterology</i> , 2019, 156, 130-144.e10.	1.3	46
64	Autocrine VEGF Signaling Promotes Proliferation of Neoplastic Barrett's Epithelial Cells Through a PLC-Dependent Pathway. <i>Gastroenterology</i> , 2014, 146, 461-472.e6.	1.3	45
65	NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 439-453.	4.5	43
66	Unlike Esophageal Squamous Cells, Barrett's Epithelial Cells Resist Apoptosis by Activating the Nuclear Factor- κ B Pathway. <i>Cancer Research</i> , 2009, 69, 672-677.	0.9	42
67	Proton Pump Inhibitors Decrease Eotaxin-3 Expression in the Proximal Esophagus of Children with Esophageal Eosinophilia. <i>PLoS ONE</i> , 2014, 9, e101391.	2.5	42
68	Hypoxia-inducible factor-2 α plays a role in mediating oesophagitis in GORD. <i>Gut</i> , 2017, 66, 1542-1554.	12.1	41
69	Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. <i>Contemporary Clinical Trials</i> , 1994, 15, 335-348.	1.9	40
70	Mucosal pathogenesis in gastroesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2020, 32, e14022.	3.0	40
71	A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. <i>American Journal of Gastroenterology</i> , 2017, 112, 734-739.	0.4	39
72	A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2 α : a potential role for targeting HIF-2 α to prevent and treat reflux esophagitis. <i>Current Opinion in Pharmacology</i> , 2017, 37, 93-99.	3.5	39

#	ARTICLE	IF	CITATIONS
73	New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. Gastroenterology, 2018, 154, 1594-1601.	1.3	39
74	Re-examination of the Cost-Effectiveness of Surgical Versus Medical Therapy in Patients With Gastroesophageal Reflux Disease: The Value of Long-Term Data Collection. American Journal of Gastroenterology, 2004, 99, 1023-1028.	0.4	38
75	White Paper AGA: Drug Development for Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2017, 15, 1173-1183.	4.4	37
76	Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. Digestive Diseases and Sciences, 2019, 64, 1089-1097.	2.3	37
77	Disputing dysplasia. Gastroenterology, 2001, 120, 1864-1868.	1.3	35
78	Integrated Approach to Treatment of Children and Adults With Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America, 2008, 18, 195-217.	1.4	34
79	The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut, 1997, 41, 710-711.	12.1	33
80	Clinical Manifestations and Esophageal Complications of GERD. American Journal of the Medical Sciences, 2003, 326, 279-284.	1.1	33
81	Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 617-623.	1.9	31
82	The Natural History of Dysplasia and Cancer in Esophagitis and Barrett Esophagus. Journal of Clinical Gastroenterology, 2003, 36, S2-S5.	2.2	29
83	Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. American Journal of Gastroenterology, 2003, 98, 759-762.	0.4	28
84	Barrett's metaplasia develops from cellular reprogramming of esophageal squamous epithelium due to gastroesophageal reflux. American Journal of Physiology - Renal Physiology, 2017, 312, G615-G622.	3.4	28
85	Managing Barrett's oesophagus. BMJ: British Medical Journal, 2003, 326, 892-894.	2.3	25
86	Thermal Ablation of Barrett's Esophagus: A Heated Debate. American Journal of Gastroenterology, 2006, 101, 1770-1772.	0.4	25
87	Screening and surveillance for Barrett's esophagus—an unresolved dilemma. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 470-471.	1.7	25
88	Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis. Gastrointestinal Endoscopy, 2018, 87, 1207-1214.e3.	1.0	25
89	Laser photoablation of Barrett's epithelium: Burning issues about burning tissues. Gastroenterology, 1993, 104, 1855-1858.	1.3	24
90	Management of Nondysplastic Barrett's Esophagus: Where Are We Now?. American Journal of Gastroenterology, 2009, 104, 805-808.	0.4	24

#	ARTICLE	IF	CITATIONS
91	New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitor Management Before Diagnostic Endoscopy. Gastroenterology, 2018, 154, 1217-1221.e3.	1.3	24
92	Surgery for Gastroesophageal Reflux Disease: Esophageal Impedance to Progress?. Clinical Gastroenterology and Hepatology, 2009, 7, 1264-1265.	4.4	23
93	In oesophageal squamous cells, nitric oxide causes S-nitrosylation of Akt and blocks SOX2 (sex) Tj ETQq1 1 0.784314 rgBT /Overlock 10 12.1 22	12.1	22
94	In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. Gastroenterology, 2021, 160, 2072-2088.e6.	1.3	22
95	Columnar-lined esophagus: Definitions. Chest Surgery Clinics of North America, 2002, 12, 1-13.	0.7	21
96	The Effect of Proton Pump Inhibitors on Barrett's Esophagus. Gastroenterology Clinics of North America, 2015, 44, 415-424.	2.2	20
97	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1471-1474.	4.4	20
98	Proton Pump Inhibitors. Medical Clinics of North America, 2019, 103, 1-14.	2.5	20
99	Esophageal complications of gastroesophageal reflux disease: Presentation, diagnosis, management, and outcomes. Clinical Cornerstone, 2003, 5, 41-48.	0.7	18
100	Development and Characterization of a Surgical Mouse Model of Reflux Esophagitis and Barrett's Esophagus. Journal of Gastrointestinal Surgery, 2014, 18, 234-241.	1.7	18
101	Controversies in Barrett Esophagus. Mayo Clinic Proceedings, 2014, 89, 973-984.	3.0	18
102	Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion. American Journal of Physiology - Renal Physiology, 2015, 309, G146-G161.	3.4	18
103	Lower esophageal sphincter muscle of patients with achalasia exhibits profound mast cell degranulation. Neurogastroenterology and Motility, 2021, 33, e14055.	3.0	18
104	GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. American Journal of Physiology - Renal Physiology, 2007, 293, G19-G24.	3.4	17
105	Barrett's Esophagus: Is the Goblet Half Empty?. Clinical Gastroenterology and Hepatology, 2012, 10, 1237-1238.	4.4	17
106	Does Barrett's Esophagus Regress after Surgery (or Proton Pump Inhibitors). Digestive Diseases, 2014, 32, 156-163.	1.9	17
107	Speculation as to why the Frequency of Eosinophilic Esophagitis Is Increasing. Current Gastroenterology Reports, 2018, 20, 26.	2.5	17
108	Barrett's esophagus: A molecular perspective. Current Gastroenterology Reports, 2005, 7, 177-181.	2.5	16

#	ARTICLE	IF	CITATIONS
109	Stem cells in Barrett's esophagus: HALOs or horns?. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 41-43.	1.0	16
110	Cardiac Metaplasia: Follow, Treat, or Ignore?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2052-2058.	2.3	16
111	Refractory Gastroesophageal Reflux Disease and Functional Heartburn. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 343-359.	1.4	16
112	In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G464-G478.	3.4	16
113	Mast cell effects on esophageal smooth muscle and their potential role in eosinophilic esophagitis and achalasia. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G319-G327.	3.4	16
114	Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 389-404.	4.5	15
115	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Journal of Gastroenterology</i> , 2019, 54, 837-844.	5.1	15
116	Banding Without Resection (Endoscopic Mucosal Ligation) as a Novel Approach for the Ablation of Short-Segment Barrett's Epithelium: Results of a Pilot Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 1640-1645.	0.4	13
117	Barrett's Esophagus: The American Perspective. <i>Digestive Diseases</i> , 2013, 31, 10-16.	1.9	13
118	Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. <i>Gut</i> , 2012, 61, 222-232.	12.1	13
119	Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 437-450.	2.2	12
120	Mechanisms and pathophysiology of Barrett oesophagus. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 605-620.	17.8	11
121	Barrett's Esophagus: Clinical Issues. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 1-7.	1.4	10
122	Barrett's Esophagus Without Dysplasia: Wait or Ablate?. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1926-1928.	2.3	10
123	Medical or invasive therapy for GERD: An acidulous analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 81-88.	4.4	8
124	Endoscopic Therapy in Barrett's Esophagus: When and How?. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 509-521.	1.5	8
125	The Durability of Antireflux Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 913.	7.4	8
126	Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 9-14.	2.2	8

#	ARTICLE	IF	CITATIONS
127	Cardiac mucosa: the heart of the problem. <i>Gut</i> , 2015, 64, 1673-1674.	12.1	7
128	A 59-Year-Old Woman With Gastroesophageal Reflux Disease and Barrett Esophagus. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 466.	7.4	6
129	Use of Hemoclips and Other Measures to Prevent Bleeding During Colonoscopy by Gastroenterologists in Veterans Affairs Hospitals. <i>American Journal of Gastroenterology</i> , 2014, 109, 288-290.	0.4	6
130	Barrett's Esophagus. , 2013, , 723-738.		5
131	A human Barrett's esophagus organoid system reveals epithelial-mesenchymal plasticity induced by acid and bile salts. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G598-G614.	3.4	5
132	Screening for Barrett's oesophagus: are we looking for the right thing?. <i>Gut</i> , 2021, 70, 1426-1427.	12.1	4
133	Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia. <i>Gut</i> , 2017, 66, 1173-1174.	12.1	3
134	A new candidate for the progenitor cell of Barrett metaplasia. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 7-8.	17.8	3
135	American Registry of Pathology Expert Opinions: Evaluating Patients with Eosinophilic Esophagitis: Practice Points for Endoscopists and Pathologists. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151418.	1.3	3
136	Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 105-115.	1.4	3
137	Risk of community-acquired pneumonia after acid-suppressive drugs. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 72-73.	1.7	2
138	Barrett Esophagus and Esophageal Adenocarcinoma. , 0, , 826-848.		2
139	Of Mice and Men and Metaplasia. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 4, 183-184.	4.5	2
140	Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , 2019, 15, 111-113.	0.1	2
141	Spastic secondary contractile patterns identified by FLIP panometry in symptomatic patients with unremarkable high-resolution manometry. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14321.	3.0	2
142	Timing of Resumption of Anticoagulation After Polypectomy and Frequency of Post-procedural Complications: A Post-hoc Analysis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3210-3219.	2.3	2
143	Screening and surveillance for Barrett's esophagus. <i>Current GERD Reports</i> , 2007, 1, 179-184.	0.1	1
144	543 Support for Wound Healing As the Mechanism for Columnar Metaplasia of the Esophagus in a Rodent Model of Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, S-109.	1.3	1

#	ARTICLE	IF	CITATIONS
145	Histologic Study of the Esophagogastric Junction of Organ Donors Reveals Novel Glandular Structures in Normal Esophageal and Gastric Mucosae. Clinical and Translational Gastroenterology, 2021, 12, e00346.	2.5	1
146	What is the long-term effect of high-dose versus standard-dose omeprazole in patients with dyspepsia?. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 12-13.	1.7	0
147	Endoscopic Evaluation of the Esophagus and Endoscopic Ultrasonography of the Esophagus. , 2019, , 85-114.		0
148	Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?. Gastroenterology, 2020, 159, 1653-1655.	1.3	0
149	Invited response to letter to the editor by Tustumi et al. Neurogastroenterology and Motility, 2021, 33, e14114.	3.0	0
150	Implications of Recent Revelations from Basic and Clinical Studies of Barrett's Esophagus for Screening and Surveillance Strategies. Foregut, 2021, 1, 86-92.	0.5	0
151	IL-13/IL-4R α Signaling Increases Tension in Human Circular and Longitudinal Esophageal Smooth Muscle Through Distinct Molecular Pathways: Potential Contribution to Reduced Esophageal Distensibility in EoE. FASEB Journal, 2021, 35, .	0.5	0
152	Evaluation and Management of Patients with PPI-Refractory Heartburn. Current Treatment Options in Gastroenterology, 2021, 19, 134-152.	0.8	0
153	Nanofabricated Sensing Electrodes in a Batteryless Endoluminal Sensing Telemeter for Diagnosis of Gastroesophageal Reflux Disease (GERD). , 2010, , .		0
154	Relationship of Eosinophilic Esophagitis to Gastroesophageal Reflux. , 2012, , 135-146.		0
155	Endoscopic Evaluation of the Esophagus. , 2013, , 101-111.		0